BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
FOLFIRI Sensitive: C4 – Case Studies
BMJ Case Rep - 3 weeks (NewC4)
|
FOLFIRI Sensitive: C4 – Case Studies
BMJ Case Rep - 3 weeks - (New C4)
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
FOLFIRINOX Sensitive: C4 – Case Studies
BMJ Case Rep - 3 weeks (NewC4)
|
FOLFIRINOX Sensitive: C4 – Case Studies
BMJ Case Rep - 3 weeks - (New C4)
|
BRCA1 mutation
|
Pancreatic Cancer
|
BRCA1 mutation
|
Pancreatic Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Peritoneal Cancer
|
BRCA1 mutation
|
Peritoneal Cancer
|
bevacizumab + olaparib Sensitive: A1 - Approval
|
bevacizumab + olaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Peritoneal Cancer
|
BRCA1 mutation
|
Peritoneal Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
bevacizumab + olaparib Sensitive: A1 - Approval
|
bevacizumab + olaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Peritoneal Cancer
|
BRCA1 mutation
|
Peritoneal Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Peritoneal Cancer
|
BRCA1 mutation
|
Peritoneal Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Prostate Cancer
|
BRCA1 mutation
|
Prostate Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
bevacizumab + olaparib Sensitive: A1 - Approval
|
bevacizumab + olaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
pamiparib Sensitive: A1 - Approval
|
pamiparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
talazoparib Sensitive: A1 - Approval
|
talazoparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
pamiparib Sensitive: A1 - Approval
|
pamiparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Prostate Cancer
|
BRCA1 mutation
|
Prostate Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Peritoneal Cancer
|
BRCA1 mutation
|
Peritoneal Cancer
|
pamiparib Sensitive: A1 - Approval
|
pamiparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
bevacizumab Resistant: A2 - Guideline
|
bevacizumab Resistant: A2 - Guideline
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
PARP inhibitor Sensitive: A2 - Guideline
|
PARP inhibitor Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Breast Cancer
|
BRCA1 mutation
|
Breast Cancer
|
talazoparib Sensitive: A2 - Guideline
|
talazoparib Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
eribulin mesylate Sensitive: A2 - Guideline
|
eribulin mesylate Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Breast Cancer
|
BRCA1 mutation
|
Breast Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
talazoparib Sensitive: A2 - Guideline
|
talazoparib Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
PARP inhibitor Sensitive: A2 - Guideline
|
PARP inhibitor Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Hormone Receptor Positive Breast Cancer
|
BRCA1 mutation
|
Hormone Receptor Positive Breast Cancer
|
PARP inhibitor Sensitive: A2 - Guideline
|
PARP inhibitor Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
rucaparib Sensitive: A2 - Guideline
|
rucaparib Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Prostate Cancer
|
BRCA1 mutation
|
Prostate Cancer
|
niraparib Sensitive: B - Late Trials
|
niraparib Sensitive: B - Late Trials
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
CaT Sensitive: B - Late Trials
|
CaT Sensitive: B - Late Trials
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
ABT-888 Sensitive: B - Late Trials
|
ABT-888 Sensitive: B - Late Trials
|
BRCA1 mutation
|
Breast Cancer
|
BRCA1 mutation
|
Breast Cancer
|
ABT-888 Sensitive: B - Late Trials
|
ABT-888 Sensitive: B - Late Trials
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
ABT-888 Sensitive: B - Late Trials
|
ABT-888 Sensitive: B - Late Trials
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
atezolizumab Sensitive: B - Late Trials
|
atezolizumab Sensitive: B - Late Trials
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
olaparib + cediranib Sensitive: B - Late Trials
|
olaparib + cediranib Sensitive: B - Late Trials
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
trabectedin Sensitive: B - Late Trials
|
trabectedin Sensitive: B - Late Trials
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
PARP inhibitor Sensitive: B - Late Trials
|
PARP inhibitor Sensitive: B - Late Trials
|
BRCA1 mutation
|
Hormone Receptor Positive Breast Cancer
|
BRCA1 mutation
|
Hormone Receptor Positive Breast Cancer
|
ABT-888 Sensitive: B - Late Trials
|
ABT-888 Sensitive: B - Late Trials
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
ABT-888 Sensitive: B - Late Trials
|
ABT-888 Sensitive: B - Late Trials
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
fluzoparib Sensitive: B - Late Trials
|
fluzoparib Sensitive: B - Late Trials
|
BRCA1 mutation
|
Breast Cancer
|
BRCA1 mutation
|
Breast Cancer
|
ribociclib Sensitive: B - Late Trials
|
ribociclib Sensitive: B - Late Trials
|
BRCA1 mutation
|
Hormone Receptor Positive Breast Cancer
|
BRCA1 mutation
|
Hormone Receptor Positive Breast Cancer
|
talazoparib Sensitive: B - Late Trials
|
talazoparib Sensitive: B - Late Trials
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
atezolizumab Resistant: B - Late Trials
|
atezolizumab Resistant: B - Late Trials
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
CPB Sensitive: B - Late Trials
|
CPB Sensitive: B - Late Trials
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
rucaparib Resistant: B - Late Trials
|
rucaparib Resistant: B - Late Trials
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
niraparib Sensitive: B - Late Trials
|
niraparib Sensitive: B - Late Trials
|
BRCA1 mutation
|
Breast Cancer
|
BRCA1 mutation
|
Breast Cancer
|
CX-5461 Sensitive: B - Late Trials
|
CX-5461 Sensitive: B - Late Trials
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
CX-5461 Sensitive: B - Late Trials
|
CX-5461 Sensitive: B - Late Trials
|
BRCA1 mutation
|
NSCLC
|
BRCA1 mutation
|
NSCLC
|
rucaparib Sensitive: C1 - Off-label
|
rucaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Cholangiocarcinoma
|
BRCA1 mutation
|
Cholangiocarcinoma
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Pancreatic Cancer
|
BRCA1 mutation
|
Pancreatic Cancer
|
rucaparib Sensitive: C1 - Off-label
|
rucaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
niraparib Sensitive: C1 - Off-label
|
niraparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Endometrial Cancer
|
BRCA1 mutation
|
Endometrial Cancer
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Mesothelioma
|
BRCA1 mutation
|
Mesothelioma
|
rucaparib Sensitive: C1 - Off-label
|
rucaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Germ Cell Tumors
|
BRCA1 mutation
|
Germ Cell Tumors
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
rucaparib Sensitive: C1 - Off-label
|
rucaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Ovarian Serous Adenocarcinoma
|
BRCA1 mutation
|
Ovarian Serous Adenocarcinoma
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
pamiparib Sensitive: C1 - Off-label
|
pamiparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
talazoparib Sensitive: C1 - Off-label
|
talazoparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
CRC
|
BRCA1 mutation
|
CRC
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Prostate Cancer
|
BRCA1 mutation
|
Prostate Cancer
|
talazoparib Sensitive: C1 - Off-label
|
talazoparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
RCC
|
BRCA1 mutation
|
RCC
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Endometrial Cancer
|
BRCA1 mutation
|
Endometrial Cancer
|
niraparib Sensitive: C1 - Off-label
|
niraparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
BRCA1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Gallbladder Cancer
|
BRCA1 mutation
|
Gallbladder Cancer
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Gastrointestinal Cancer
|
BRCA1 mutation
|
Gastrointestinal Cancer
|
rucaparib Sensitive: C1 - Off-label
|
rucaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria
|
tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
Pancreatic Cancer
|
BRCA1 mutation
|
Pancreatic Cancer
|
ABT-888 Sensitive: C2 – Inclusion Criteria
|
ABT-888 Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
Ovarian Serous Adenocarcinoma
|
BRCA1 mutation
|
Ovarian Serous Adenocarcinoma
|
olaparib + LY2606368 Sensitive: C2 – Inclusion Criteria
|
olaparib + LY2606368 Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
olaparib + CP-675206 Sensitive: C2 – Inclusion Criteria
|
olaparib + CP-675206 Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
bevacizumab + olaparib + durvalumab Sensitive: C2 – Inclusion Criteria
|
bevacizumab + olaparib + durvalumab Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
carboplatin + paclitaxel Sensitive: C2 – Inclusion Criteria
|
carboplatin + paclitaxel Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
IMP4297 Sensitive: C2 – Inclusion Criteria
|
IMP4297 Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
olaparib + durvalumab Sensitive: C2 – Inclusion Criteria
|
olaparib + durvalumab Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
SC10914 Sensitive: C2 – Inclusion Criteria
|
SC10914 Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
Prostate Cancer
|
BRCA1 mutation
|
Prostate Cancer
|
olaparib + AZD5363 Sensitive: C2 – Inclusion Criteria
|
olaparib + AZD5363 Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
Breast Cancer
|
BRCA1 mutation
|
Breast Cancer
|
olaparib + AZD5363 Sensitive: C2 – Inclusion Criteria
|
olaparib + AZD5363 Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
olaparib + durvalumab Sensitive: C2 – Inclusion Criteria
|
olaparib + durvalumab Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria
|
tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
Ovarian Cancer
|
BRCA1 mutation
|
Ovarian Cancer
|
olaparib + durvalumab + CP-675206 Sensitive: C2 – Inclusion Criteria
|
olaparib + durvalumab + CP-675206 Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
Solid Tumor
|
BRCA1 mutation
|
Solid Tumor
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|